Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial
Federico Martinón-Torres, Alfonso Carmona Martinez, Róbert Simkó, Pilar Infante Marquez, Josep-Lluis Arimany, Francisco Gimenez-Sanchez, José Antonio Couceiro Gianzo, Éva Kovács, Pablo Rojo, Huajun Wang, Chiranjiwi Bhusal, Daniela Toneatto, Federico Martinón-Torres, Alfonso Carmona Martinez, Róbert Simkó, Pilar Infante Marquez, Josep-Lluis Arimany, Francisco Gimenez-Sanchez, José Antonio Couceiro Gianzo, Éva Kovács, Pablo Rojo, Huajun Wang, Chiranjiwi Bhusal, Daniela Toneatto
Abstract
Objectives: This phase IIIb, open-label, multicentre, extension study (NCT01894919) evaluated long-term antibody persistence and booster responses in participants who received a reduced 2 + 1 or licensed 3 + 1 meningococcal serogroup B vaccine (4CMenB)-schedule (infants), or 2-dose catch-up schedule (2-10-year-olds) in parent study NCT01339923.
Materials and methods: Children aged 35 months to 12 years (N = 851) were enrolled. Follow-on participants (N = 646) were randomised 2:1 to vaccination and non-vaccination subsets; vaccination subsets received an additional 4CMenB dose. Newly enrolled vaccine-naïve participants (N = 205) received 2 catch-up doses, 1 month apart (accelerated schedule). Antibody levels were determined using human serum bactericidal assay (hSBA) against MenB indicator strains for fHbp, NadA, PorA and NHBA. Safety was also evaluated.
Results: Antibody levels declined across follow-on groups at 24-36 months versus 1 month post-vaccination. Antibody persistence and booster responses were similar between infants receiving the reduced or licensed 4CMenB-schedule. An additional dose in follow-on participants induced higher hSBA titres than a first dose in vaccine-naïve children. Two catch-up doses in vaccine-naïve participants induced robust antibody responses. No safety concerns were identified.
Conclusion: Antibody persistence, booster responses, and safety profiles were similar with either 2 + 1 or 3 + 1 vaccination schedules. The accelerated schedule in vaccine-naïve children induced robust antibody responses.
Keywords: 2 + 1 schedule; Antibody persistence; Booster response; Children; Infants; Meningococcal B vaccine; Open-label randomised clinical trial; Safety.
Copyright © 2017 GlaxoSmithKline SA. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed